High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study von Leblanc, Thierry, Landman-Parker, Judith, Auclerc, Marie-Françoise, Desseaux, Krystell, Vermylen, Christiane, Schmitt, Claudine, Gandemer, Virginie, Lejars, Odile, Vannier, Jean-Pierre, Demeocq, François, Berthou, Christian, Couillault, Gérard, Pautard, Brigitte, Berger, Claire, De Lumley, Lionel, Debré, Marianne, Michel, Gérard, Perel, Yves, Leverger, Guy, Baruchel, Andre

Volltext